GSK's Taflinar pockets breakthrough label

Share this article:

GlaxoSmithKline's Tafinlar garnered additional FDA attention Monday when the regulator granted the drug Breakthrough Therapy status for patients with metastatic BRAF V600E mutation-positive non-small-cell lung cancer who have already undergone platinum-containing chemotherapy.

Phase-II data helped secure the designation, which accelerates the regulatory review process. The FDA approved this same drug January 9 for use with Mekinist among patients with unresectable metastatic melanoma with BRAF V600 or V600K mutation or for treating metastatic melanoma with either of these mutations.

Tafinlar was approved last May for use as a single-agent oral therapy in treating unresectable or metastatic melanoma in patients with the BRAF V600 or V600K mutation. And this month, the FDA also sanctioned single-pill combination use of Tafinlar and Mekinist, GSK's other drug for patients whose melanoma cells have the V600E or V600K mutation in the BRAF gene.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.